Clinical Trials & Studies
About Our Clinical Trials & Studies
Members from each of our divisions are leading research projects. Explore current studies below.
Multiple Sclerosis
Multiple Sclerosis
Adam Carpenter, MD
- BEAT-MS (2020-2024)
- A Phase III, multicentre, randomized, parallel-group, double-blinded, placenbo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive MS (2011-2023)
- A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab in patients with MS (2022-2028)
William Schmalstieg, MD
- DELIVER-MS: Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (2018-2026)
Headache
Headache
Abby Metzler, MD
- TRIUMPH: Preventative Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems (2020-2026)
Sleep
Sleep
Michael Howell, MD, FAAN, FAASM
- NAPS2: North American Prodromal Synucleinopathy Consortium Stage 2 (2021-2023)
Education
Education
Jessica Goldstein, MD
- Promoting lifelong learning through development and implementation of a neurology digital education scholars program (2023-2024)
Kristine Domingo, DO
- Movement Disorders Fellowship Program support (2021-2023)
Neuromuscular Medicine (Adult & Pediatric)
Neuromuscular Medicine (Adult & Pediatric)
Jeffrey A. Allen, MD
- INCbase Registry (2021-2024)
- ARDA+: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy (2021-2025)
- A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) (2022-2027)
- ADHERE: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (2021-2025)
- ADHERE+: Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Subcutaneously Administered Efgartigimod with rHuPH20 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (2022-2027)
Atsushi Asakura, MD
- Targeting Vascular Endothelium for Muscular Dystrophy Therapy (2021-2024)
- Systemic delivery of muscle stem cell for muscle disease therapy (2022-2024)
Peter B. Kang, MD, FAAN, FAAP
- Foundations for a Phase 1 clinical trial of cell-based therapy for Duchenne muscular dystrophy (2022-2024)
- Surveillance of muscular dystrophy in the Southeastern United States (2021-2023)
- Natural History Study of Cockayne Syndrome (2022-2023)
- GRASP: Defining Clinical Endpoints in LGMD Subtype 2E, 2D, 2F and 2C (2021-2023)
Peter Karachunski, MD
- An Open-Label, Safety Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy (2010-2025)
- ACT DMD: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension (2017-2027)
- MDA MOVR Registry (2018-2023)
- A Prospective, Long Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy (SMA) (2020-2025)
- A Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients with Myotonic Dystrophy Type 1, Followed by an Open-Label Extension (2022-2025)
- A Long-term Observational Study Evaluating Eteplirsen in Patients with Duchenne Muscular Dystrophy under Conditions of Routine Clinical Practice (2019-2023)
- Schulze Muscular Dystrophy Ability Clinical Study (2021-2023)
Georgios Manousakis, MD
- MINT: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study with Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults with Myasthenia Gravis (2021-2024)
- Givinostat Extension (2020-2026)
Christina Pacak, MD
- Mechanisms and Treatment of Cardiac and Skeletal Muscular Dysfunction in Barth Syndrome (2021-2024)
David Walk, MD
- Clinic-based Multicenter ALS Natural History Data Collection (2022-2026)
- Healey ALS Platform Trial (2020-2025)
- PLEO-CMT-FU: International, multi-center, double blind 9-month follow-up extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A (2021-2027)
Research Centers
Research Labs
Service Labs
Pediatric Neurology
Pediatric Neurology
Sonya Wang, MD
- NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity (2022-2026)
- Effects of Music-Based Intervention (MBI) on Neurodevelopment and Pain Response in Preterm Infants (2019-2023)
- Lacosamide to Treat Neonatal Seizures (2022-2023)
Research Lab
Epilepsy
Epilepsy
Thomas R. Henry, MD
- Investigation of Long Term Multichannel Intracranial EEG with Computational Intelligence for the Identification of Seizure Onset Zone in Epilepsy (2019-2024)
Sima Patel, MD
- Use of Lacosamide (LCS) in Elderly Patients with Epilepsy (2021-2023)
Research Lab
Memory
Memory
Karen H. Ashe, MD
- Caspase-2 Probe Compounds (2019-2023)
- Role of Tau Cleavage and Phosphorylation in Tauopathy (2018-2023)
- Curing Alzheimer's Disease: A Proposal for the Lucas Brothers Foundation (2017-2023)
- Repairing synapses in neurodegenerative disorders by inhibiting caspase-2 (2022-2023)
- Repairing neurotransmission in Alzheimer's disease and related disorders by targeting caspase-2 (2022-2024)
William G. Mantyh, MD
- Dementia prevalence, APOE, and blood-based biomarkers of AD in Native American communities (2022-2027)
Research Center & Lab
Movement Disorders
Movement Disorders
Scott Cooper, MD, PhD
- INTREPID: Implantable Neurostimulator for the Treatment of Parkinson's Disease (2013-2023)
- Targeted Pathway Activation for Postural Instability & Gait Disorder in Parkinson's Disease (2022-2027)
- DBS Telehealth Survey (2022-2023)
Luke A. Johnson, PhD
- The effects of parkinsonism and deep brain stimulation on basal ganglia-thalamocortical circuitry during sleep-wake behavior (2019-2024)
Colum MacKinnon, PhD
- Neuroplasticity and the expression of parkinsonian motor signs in idiopathic REM sleep behavior disorder (2022-2025)
- Subthalamic Nucleus Plasticity in the Parkinsonian State (2019-2024)
- SPARX3: Study in Parkinson Disease of Exercise Phase 3 Clinical Trial (2019-2023)
- Continuous Wearable Monitor for the Detection and Release of Freezing of Gait (2021-2023)
Paul Tuite, MD
- Web-based Automated Imaging Differentiation of Parkinsonism (wAID-P) (2021-2023)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease (2020-2024)
Jerrold L. Vitek, MD, PhD
- Circuit-based deep brain stimulation for Parkinson's disease (2016-2023)
- Basal Ganglia Cortical Coupling and Connectivity Changes in PD and DBS (2019-2024)
- Neurophysiological Mechanisms Underlying Parkinsonian Motor Signs (2021-2023)
- Neuronal Activity in MC and SMA during STN and GPi DBS in the Parkinsonian Monkey (2022-2025)
Jing Wang, MD
- Optimizing coordinated reset deep brain stimulation for Parkinson's disease (2020-2025)
- Preclinical Testing Of Novel DBS Protocol For Long-Lasting Therapeutic Effects (2019-2023)
Research Centers
Research Labs
Stroke & Neurocritical Care
Stroke & Neurocritical Care
Muhammad Affan, MBBS
- MASTERS-2: MultiStem Administration for Stroke Treatment and Enhancement Recovery Study (2020-2025)
Oladi Bentho, MD, MS
- SATURN: Statins use in ICH patients (2019-2026)
- ASPIRE: Anticoagulation in ICH Survivors for Stroke Prevention & Recovery (2019-2024)
Andrew W. Grande, MD, FAHA, FAANS
- CREST-2/CREST-H: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (Hemodynamics) (2015-2025/2022-2023)
- C2LOE: Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial (2022-2023)
Praveen Hariharan, MBBS
- RHAPSODY-2: A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (2022-2028)
Haitham Hussein, MD, MSc, FAAN, FAHA
- CAPTIVA: Comparison of Anticoagulation and Antiplatetlet Therapies for Intracranial Vascular Atherostenosis (2021-2026)
Kamakshi Lakshminarayan, MBBS, PhD, MS
- DISCOVERY: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (2019-2025)
- Sleep SMART: Sleep for Stroke Management and Recovery Trial (2018-2024)
Margy McCullough-Hicks, MD
- PRECISE: Perfusion imaging to identify posterior circulation candidates for thrombectomy (2021-2023)
Benjamin R. Miller, MD
- ARCADIA: Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryptogenic Stroke (2017-2023)
- ARCADIA CSI: ARCADIA - Cognition and Silent Infarcts (2019-2024)
Christopher Streib, MD, MS
- TIMELESS: A Phase III, prospective, double-blind, randomized, placebo-controlled trial of Tenecteplace in imaging-eligible, late-window patients to assess the efficacy and safety of Tenecteplase (2019-2024)
- FASTEST: Recombinant Factor VIIa for Acute Hemorrhagic Stroke Administered at Earliest Time trial (2020-2025)
- Neuro-AFib (2020-2023)
- Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy & Safety of IV BIIB093 (Gilbenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (2018-2023)